Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
← catalyst calendarNCT07106762 · readout in 891 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
470estimated
Sites
163
Countries
Argentina, Australia, Austria +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-30 | actual | When the study began enrolling |
| Primary completion | 2029-01-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-11-18 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Urothelial Cancer
Interventions
- Drug: Iza-bren — also filed as BMS-986507, BL-B01D1, Izalontamab brengitecan
- Drug: Cisplatin
- Drug: Gemcitabine
- Drug: Carboplatin
Primary outcomes
what the primary-completion date above is the date OFPhase 2: Recommended Phase 3 Dose (RP3D) of BMS-986507
measured Approximately 3 months
Phase 3: Progression-Free Survival (PFS)
measured Up to 5 years
Phase 3: Overall Survival (OS)
measured Up to 5 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed